Scienture Holdings, Inc. - SIC # 6794 - PATENT OWNERS AND LESSORS

Ticker Exchange SIC # Website Latest Ticker
SCNX Nasdaq 6794 scienture.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scienture Holdings, Inc.

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion - May 18th, 2026 6:38 am
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline - May 7th, 2026 6:05 am
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041 - May 6th, 2026 6:05 am
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Apr 15th, 2026 6:05 am
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead - Apr 6th, 2026 6:05 am
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update - Mar 30th, 2026 6:07 am
BC-Most Active Stocks - Mar 11th, 2026 8:30 am
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - Mar 11th, 2026 6:05 am
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - Feb 3rd, 2026 6:05 am
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment - Jan 14th, 2026 6:05 am
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA - Dec 22nd, 2025 6:05 am
Scienture, BlinkRx announce strategic collaboration to expand access to Arbli - Dec 11th, 2025 6:20 am
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - Dec 10th, 2025 6:05 am
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Dec 8th, 2025 7:00 am
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 - Dec 2nd, 2025 6:05 am
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Dec 1st, 2025 7:00 am
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update - Nov 13th, 2025 6:05 am
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction - Nov 13th, 2025 5:50 am
Scienture Holdings: Q3 Earnings Snapshot - Nov 12th, 2025 3:49 pm
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans - Nov 4th, 2025 6:05 am